Biostatistics LeadSanofi, Cambridge, MA, USACambridge, Massachusetts, United States
OC 01.4 - Interim analysis of joint outcomes in adult and adolescent patients with severe hemophilia A receiving efanesoctocog alfa during the phase 3 XTEND-ed long-term extension study
Saturday, June 22, 202413:45 – 14:00 ICT
OC 13.3 - Pooled Analysis of the Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients With Previously Treated Immune Thrombocytopenia: Phase 2 Study
Sunday, June 23, 202410:00 – 10:15 ICT
